Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence

• Hauptverfasser: Nur Syahidah Nor Hisam (Verfasst von), Azizah Ugusman (Verfasst von), Nor Fadilah Rajab (Verfasst von), Mohd Faizal Ahmad (Verfasst von), Michael Fenech (Verfasst von), Sze Ling Liew (Verfasst von), Nur Najmi Mohamad Anuar (Verfasst von)
• Format: Buch
• Veröffentlicht: MDPI AG, 2021-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Combination therapy emerges as a fundamental scheme in cancer. Many targeted therapeutic agents are developed to be used with chemotherapy or radiation therapy to enhance drug efficacy and reduce toxicity effects. ABT-263, known as navitoclax, mimics the BH3-only proteins of the BCL-2 family and has...